Our Mission

We are a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Our robust pipeline includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE), as well as wet age-related macular degeneration (wAMD).

Leveraging our next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. We are well positioned with core capabilities, which include clinical development and in-house manufacturing expertise, specifically in process development and assay development.

Our team has extensive clinical development experience and is laser-focused on advancing novel gene therapies for patients with rare and ocular diseases.

Our Leadership Team

Print All
Amber Salzman, Ph.D. President and Chief Executive Officer
Leone Patterson Chief Financial Officer
Athena Countouriotis, M.D. Senior Vice President, Chief Medical Officer
Mehdi Gasmi, Ph.D. Chief Science and Technology Officer
Jennifer Cheng, Ph.D., J.D. Vice President and General Counsel
Paul B. Cleveland Chairman
Eric G. Carter, M.D., Ph.D. Director
Mitchell Finer, Ph.D. Co-Founder
Patrick Machado, J.D. Director
Amber Salzman, Ph.D. President and Chief Executive Officer
Richard N. Spivey, Pharm.D., Ph.D. Director
Thomas F. Woiwode, Ph.D. Director

Contact Us

Adverum Biotechnologies
1035 O’Brien Drive
Menlo Park, CA 94025
Tel: 650-272-6269
Fax: 650-362-1908
General Inquiry: info@adverum.com

  • *Indicates required field